The short version of hGH fragment fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-18 and is reviewed periodically as new material appears.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Lundberg, M.D, recommended that third-party payers and the public should question paying for this procedure "until or unless additional honest experimentation demonstrates an actual effect." There is no good medical evidence for the effectiveness of therapeutic touch. A Cochrane systematic review, first published in 2004, found "[t]here is no robust evidence that TT promotes healing of acute wounds", but in 2016, the authors retracted it after the validity of the reviewed studies was questioned. The American Cancer Society notes, "Available scientific evidence does not support any claims that TT can cure cancer or other diseases."
Clothing, sportswear and accessories: polyester and PVC clothing, spandex, sport shoes, wetsuits, footballs and billiard balls, skis and snowboards, rackets, parachutes, sails, tents and shelters. Electronic and photonic technologies: organic field effect transistors (OFET), light emitting diodes (OLED) and solar cells, television components, compact discs (CD), photoresists, holography. Packaging and containers: films, bottles, food packaging, barrels. Insulation: electrical and thermal insulation, spray foams. Construction and structural applications: garden furniture, PVC windows, flooring, sealing, pipes. Paints, glues and lubricants: varnish, adhesives, dispersants, anti-graffiti coatings, antifouling coatings, non-stick surfaces, lubricants. Car parts: tires, bumpers, windshields, windscreen wipers, fuel tanks, car seats. Household items: buckets, kitchenware, toys (e.g., construction sets and Rubik's Cube). Medical applications: blood bag, syringes, rubber gloves, surgical suture, contact lenses, prosthesis, controlled drug delivery and release, matrices for cell growth. Personal hygiene and healthcare: diapers using superabsorbent polymers, toothbrushes, cosmetics, shampoo, condoms. Security: personal protective equipment, bulletproof vests, space suits, ropes. Separation technologies: synthetic membranes, fuel cell membranes, filtration, ion-exchange resins. Money: polymer banknotes and payment cards. 3D printing.
=== Dating === Dating Lindow Man is difficult as samples from the body and surrounding peat have produced dates spanning a 900-year period. Although the peat encasing Lindow Man has been radiocarbon dated to about 300 BC, Lindow Man himself has a different date. Early tests at different laboratories returned conflicting dates for the body; later tests suggested a date between 2 BC and 119 AD. There has been a tendency to ascribe the body to the Iron Age period rather than Roman because of the interpretation that Lindow Man's death may have been a ritual sacrifice or execution. Explanations for why the peat in which he was found is much older have been sought. Archaeologist P. C. Buckland suggests that as the stratigraphy of the peat appears undisturbed, Lindow Man may have been deposited into a pool that was already some 300 years old. Geographer K. E. Barber has argued against this hypothesis, saying that pools at Lindow Moss would have been too shallow, and suggests that the peat may have been peeled back to allow the burial and then replaced, leaving the stratigraphy apparently undisturbed.
In a prebiotic context, they argued that seawater would likely still be buffered and ferrous iron could inhibit oxidation. Steam and hydrogen sulfide. In 1999, after Miller suffered a stroke, he donated the contents of his laboratory to Bada. In an old cardboard box, Bada discovered unanalyzed samples from modified experiments that Miller had conducted in the 1950s. In a "volcanic" apparatus, Miller had amended an aspirating nozzle to shoot a jet of steam into the reaction chamber. Using high-performance liquid chromatography and mass spectrometry, Bada's lab analyzed old samples from a set of experiments Miller conducted with this apparatus and found some higher yields and a more diverse suite of amino acids. Bada speculated that injecting the steam into the spark could have split water into H and OH radicals, leading to more hydroxylated amino acids during Strecker synthesis. In a separate set of experiments, Miller added hydrogen sulfide (H2S) to the reducing atmosphere, and Bada's analyses of the products suggested order-of-magnitude higher yields, including some amino acids with sulfur moieties. Free electrons and charged microdroplets. A 2021 work highlighted the importance of the high-energy free electrons present in the experiment. It is these electrons that produce ions and radicals, and represent an aspect of the experiment that needs to be better understood. A 2025 study used charges from sprays of water instead of lightning to produce electricity.
Sources: en.wikipedia.org
While there are many rehabilitation centres for wealthy people struggling with addiction in South Africa there are very few facilities for the poor. Some have argued that people struggling with heroin addiction are treated as the 'undeserving poor' and subject to policing rather than medical interventions. In the populous province of KwaZulu-Natal there are only two government rehab centres accessible by poor people.
== Interpretation and application == Monazite geochronology can reveal complex geological history recorded in the monazite mineral grains. The characteristic composition and age of each domain or zone represent a past geological event with a certain age. The key challenge in monazite geochronology is to correctly relate textures and compositions in each domain to the associated geological events which formed them. Even a single monazite grain may reveal a complex history, in which geologic events maybe inter-related or coeval, making discrimination difficult. The section below aims to briefly explain how composition and age data are interpreted to link different types of events.
Once again, the East Berlin communists attempted to disrupt the Berlin municipal elections, which were held on 5 December 1948 and produced a turnout of 86% and an overwhelming victory for the non-communist parties. The results effectively divided the city into East and West, the latter comprising US, British and French sectors. 300,000 Berliners demonstrated and urged the international airlift to continue, and US Air Force pilot Gail Halvorsen created "Operation Vittles", which supplied candy to German children. The Airlift was as much a logistical as a political and psychological success for the West; it firmly linked West Berlin to the United States. In May 1949, Stalin lifted the blockade. In 1952, Stalin repeatedly proposed a plan to unify East and West Germany under a single government chosen in elections supervised by the United Nations, if the new Germany were to stay out of Western military alliances, but this proposal was turned down by the Western powers. Some sources dispute the sincerity of the proposal.
Sources: en.wikipedia.org
=== Prout's hypothesis and the whole number rule === The whole number rule states that the masses of the isotopes are integer multiples of the mass of the hydrogen atom. The rule is a modified version of Prout's hypothesis proposed in 1815, to the effect that atomic weights are multiples of the weight of the hydrogen atom.
All of these scenarios increased the demands for modern refrigeration and manufactured ice. Ice producing machines like that of Carre's and Muhl's were looked to as means of producing ice to meet the needs of grocers, farmers, and food shippers. Refrigerated railroad cars were introduced in the US in the 1840s for short-run transport of dairy products, but these used harvested ice to maintain a cool temperature.
== Production == On September 2, 2021, BET+ renewed the series for a second season which premiered on August 11, 2022. On July 6, 2022, BET+ renewed the series for a third season, which premiered on February 23, 2023. On May 30, 2023, BET+ renewed the series for a fourth season, which premiered on May 23, 2024. On October 31, 2024, BET+ renewed the series for a fifth season, which premiered on January 7, 2026. On March 26, 2026, the series was renewed for a sixth season, which will move to Paramount+ after the shutdown of BET+.
=== In valvular heart disease === Periostin plays a critical role in the development of cardiac valves and in degenerative valvular heart disease. While periostin usually is localized to the subendothelial layer in healthy heart valves, its levels are highly increased in infiltrated inflammatory cells and myofibroblasts in angiogenic areas in atherosclerotic and rheumatic valvular heart disease in humans. Periostin has also been shown to increase the secretion of matrix metalloproteinase from valvular interstitial cells, endothelial cells, and macrophages. It is thought that periostin plays a role in cardiac valve complex degeneration by inducing both angiogenesis and matrix metalloproteinase production.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.